Highlight Therapeutics SL

📍 Spain👥 14 employees💰 Last funded Jul 2011
Biotechnology🌐 highlighttherapeutics.com
Website LinkedIn
Highlight, formerly known as Bioncotech Therapeutics S.L, is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Its lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system. It has the potential to rescue patients who are resistant to current checkpoint inhibitor therapy. BO-112 is currently being investigated in a range of clinical trials as a monotherapy and in combination with checkpoint inhibitors. In addition to in-house research, Highlight Therapeutics has a number of external collaborators, including Merck & Co and UCLA.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investor
All
Early stage
Mid stage
Late stage
Investor geography1 country
Spain
1
Frequently asked questions
Who invested in Highlight Therapeutics SL?
Highlight Therapeutics SL has 1 investor on record on gritt.io.
When did Highlight Therapeutics SL last raise funding?
The most recent investment in Highlight Therapeutics SL recorded on gritt.io was in July 2011.
What industry is Highlight Therapeutics SL in?
Highlight Therapeutics SL operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Highlight Therapeutics SL based?
Highlight Therapeutics SL is headquartered in Spain.